LeMaitre Vascular, Inc. (NASDAQ:LMAT) to Issue $0.16 Quarterly Dividend

LeMaitre Vascular, Inc. (NASDAQ:LMAT) declared a quarterly dividend on Thursday, October 31st, Zacks reports. Investors of record on Thursday, November 21st will be paid a dividend of 0.16 per share by the medical instruments supplier on Thursday, December 5th. This represents a $0.64 annualized dividend and a dividend yield of 0.67%. The ex-dividend date of this dividend is Thursday, November 21st.

LeMaitre Vascular has raised its dividend by an average of 13.8% per year over the last three years and has raised its dividend annually for the last 13 consecutive years. LeMaitre Vascular has a payout ratio of 31.1% indicating that its dividend is sufficiently covered by earnings. Research analysts expect LeMaitre Vascular to earn $2.09 per share next year, which means the company should continue to be able to cover its $0.64 annual dividend with an expected future payout ratio of 30.6%.

LeMaitre Vascular Stock Performance

Shares of LeMaitre Vascular stock traded up $6.49 during trading on Friday, hitting $94.88. The company’s stock had a trading volume of 343,645 shares, compared to its average volume of 123,348. The company has a fifty day simple moving average of $89.59 and a two-hundred day simple moving average of $82.98. The company has a market capitalization of $2.13 billion, a PE ratio of 56.81, a P/E/G ratio of 2.33 and a beta of 0.88. LeMaitre Vascular has a 52 week low of $45.96 and a 52 week high of $101.67.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. LeMaitre Vascular’s revenue was up 15.6% compared to the same quarter last year. During the same period last year, the business earned $0.33 EPS. As a group, analysts predict that LeMaitre Vascular will post 1.86 EPS for the current year.

Wall Street Analysts Forecast Growth

LMAT has been the subject of a number of analyst reports. Oppenheimer restated an “outperform” rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective on the stock. Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective on the stock. Finally, Barrington Research raised their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $94.57.

Insider Activity

In related news, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the sale, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 10.79% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.